<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00277797</url>
  </required_header>
  <id_info>
    <org_study_id>0102004819</org_study_id>
    <nct_id>NCT00277797</nct_id>
  </id_info>
  <brief_title>Non-Invasive Targeted Electronic Pain Control Device (&quot;Biowave System&quot;) Versus Transcutaneous Electrical Nerve Stimulation (TENS) for the Symptomatic Treatment of Chronic Low Back Pain</brief_title>
  <official_title>A Randomized, Single-Blinded, Comparative Crossover Trial of the Safety and Efficacy of a Non-Invasive Targeted Electronic Pain Control Device (&quot;Biowave System&quot;) Versus Transcutaneous Electrical Nerve Stimulation (TENS) for the Symptomatic Treatment of Chronic Low Back Pain.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biowave Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low back pain is a common condition, which extols a large cost to society from lost wages

      The Biowave System was developed by Biowave Corporation (Biowave), Norwalk, CT. Two wires
      emanate from the unit. The feed wire is attached to a large disposable input pad (&quot;Feed
      Electrode&quot;). The return wire is attached to a smaller pad (&quot;Return Electrode&quot;) over the
      source of the pain (the treatment site).

      The device sends a premixed modulated envelope of two high frequency electronic wave forms
      (&quot;Feed Signal&quot;) between the two electrodes. The beat frequency of the modulated envelope
      (&quot;d-Frequency&quot;) is equal to the difference in frequency of the two feed signals. The location
      of beat frequency formation is dependent on the size and location of the two electrodes. With
      the configuration used in the study, the beat frequency signal is believed to form
      immediately ventrally to the Return electrode. The size of the volume of tissue affected can
      be changed and is dependent upon electrode geometry and the amplitude of the Feed Signal. The
      beat frequency is a low frequency blocking signal which is believed to cause a demodulation
      in the nerve cells and a reduction of the sodium/potassium ion exchange. As a result, the
      charge polarity of the nerve cell wall is prevented from changing and is therefore unable to
      transmit pain impulses. The size of the volume of tissue affected can be changed and is
      dependent upon electrode geometry and the amplitude of the Feed Signal.

      The objective of this study is to compare the Biowave System with TENS (a currently available
      treatment) and to further evaluate its efficacy for the relief of pain in patients with
      chronic low back pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background-Low back pain is a common, costly &amp; often chronic condition, estimated to affect
      85% of people in their lifetime. A form of electronic pain control currently in use is TENS.
      Although the exact mechanism is not completely understood, it is proposed that its
      effectiveness is based on the gate control theory. Biowave has developed new patentable
      technology &amp; a related device in the field of electromedicine. The device delivers a precise
      electrical signal to a specific volume of tissue in the body, which blocks the transmission
      of pain impulses.

      Treatment Plan-Treatment will be initiated with device indicated by the order to which the
      pt. was randomized. Pts. will be connected to one of two devices hidden from view by
      application of two small round two-inch diameter electrodes to the lower back.

      Baseline-A complete medical history &amp; a physical examination will be performed. The pt. will
      complete a BPI questionnaire &amp; be randomized to one of two treatment orders: 1) Biowave
      device followed by TENS device or 2) TENS device followed by Biowave Device. 2 treatment
      sessions will be separated by at least 72 hours.

      Treatment-Prior to each treatment session, pt. will complete initial VAS evaluations. Pt.'s
      ROM will be assessed &amp; vital signs will be obtained. Pts. will complete VAS &amp; categorical
      pain assessments at end of the 20 minute treatment period.

      Post-treatment-Pts. will repeat ROM test after device has been turned off &amp; electrodes
      removed. VAS pain evaluations will be completed by the pt. at 30 &amp; 60 minutes, vital signs &amp;
      patient global impression of change will be obtained at 60 minutes following discontinuation
      of therapy. Pts. will be given VAS &amp; categorical pain assessments to be completed at 4, 6,
      12, 24 and 48 hours &amp; 1 week after treatment (to be returned by mail/fax) to assess possible
      long-term analgesic effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of mean pain scores (&quot;deep&quot; pain and &quot;superficial&quot; or &quot;surface&quot; pain visual analog scales [VAS])</measure>
    <time_frame>determined at baseline, 20 minutes after optimization of signal amplitude, and at 30 and minutes 60 following discontinuation of treatm</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Range of motion test</measure>
    <time_frame>before and after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient global impressions of change (PGIC)</measure>
    <time_frame>at end of treatment, and one day and one week after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean pain scores to assess duration of analgesia.</measure>
    <time_frame>at 4, 6, 12, 24 and 48 hours following discontinuation of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nature, frequency, and intensity of adverse events.</measure>
    <time_frame>continuous</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination and assessment of vital signs.</measure>
    <time_frame>baseline, pre-treatment, and post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>follow-up phone interviews.</measure>
    <time_frame>one day and one week post-treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Chronic Low Back Pain</condition>
  <arm_group>
    <arm_group_label>Biowave first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>First Treatment: Biowave; Second Treatment: TENS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TENS first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>First Treatment: TENS; Second Treatment: Biowave</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biowave Targeted Non-Invasive Electronic Pain Control Device</intervention_name>
    <description>This device is a non-invasive non-pharmacologic treatment for pain. It sends a premixed modulated envelope of two high frequency electronic wave forms (&quot;Feed Signals&quot;) between two electrodes.</description>
    <arm_group_label>Biowave first</arm_group_label>
    <arm_group_label>TENS first</arm_group_label>
    <other_name>Biowave</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TENS (Transcutaneous Electrical Nerve Stimulation) device</intervention_name>
    <description>This device features a bisourced, biphasic waveform. The combined constant voltage, constant-current waveform provides a strong stimulus that allows the clinician to prescribe a treatment program.</description>
    <arm_group_label>Biowave first</arm_group_label>
    <arm_group_label>TENS first</arm_group_label>
    <other_name>Empi's (St. Paul, MN) Epix XL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be male or female of any race and between the ages of 18 and 60,
             inclusive;

          -  Female patients of childbearing potential may participate if they agree to a urine
             pregnancy test and the result is negative.

          -  The primary location of pain must be the lower back area (below 12th thoracic
             vertebra) without pain radiating to the legs (a subgroup [n=10] with pain radiating to
             the legs will be studied as well. Treatment will be initiated with the device
             indicated by the treatment order to which the patient was randomized). The pain must
             have been present for 3 months or greater prior to entry into the study;

          -  Patients must have a baseline score of Â³40 mm on the VAS pain scale;

          -  If taking analgesics, patients must agree to maintain a steady regimen for the
             duration of the study;

          -  Patients must be able to understand and cooperate with study procedures; and

          -  Patients must have signed a legally effective written informed consent prior to
             entering the study.

        Exclusion Criteria:

          -  Epilepsy

          -  Pregnancy

          -  Pacemaker

          -  History of cardiac arrhythmias

          -  Implantable devices (AICD, pump, etc.)

          -  Surgical intervention during the past month for the treatment of low back pain or its
             underlying etiology

          -  Other severe pain that may confound assessment or self-evaluation of the chronic low
             back pain;

          -  Patients with pending Worker's Compensation claims, pending civil litigation pertinent
             to the cause of low back pain, currently receiving monetary compensation for the
             injury resulting in back pain, or currently involved in out-of-court settlements for
             claims pertinent to their back pain;

          -  Abuse of illicit drugs or alcohol within the last 6 months;

          -  Clinically significant or unstable medical or psychological conditions that, in the
             opinion of the investigator, would compromise participation in the study;

          -  Participation in a clinical trial for an investigational drug and/or agent within 30
             days prior to screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugh C. Hemmings Jr., MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.biowave.com</url>
    <description>Sponsor Website</description>
  </link>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2006</study_first_submitted>
  <study_first_submitted_qc>January 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2006</study_first_posted>
  <last_update_submitted>June 13, 2013</last_update_submitted>
  <last_update_submitted_qc>June 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low Back Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

